Cargando…
Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique
One of the most revolutionary technologies in recent years in the field of molecular biology is CRISPR-Cas9. CRISPR technology is a promising tool for gene editing that provides researchers the opportunity to easily alter DNA sequences and modify gene function. Its many potential applications includ...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920621/ https://www.ncbi.nlm.nih.gov/pubmed/29731717 http://dx.doi.org/10.3389/fphar.2018.00396 |
_version_ | 1783317863695646720 |
---|---|
author | Marangi, Michele Pistritto, Giuseppa |
author_facet | Marangi, Michele Pistritto, Giuseppa |
author_sort | Marangi, Michele |
collection | PubMed |
description | One of the most revolutionary technologies in recent years in the field of molecular biology is CRISPR-Cas9. CRISPR technology is a promising tool for gene editing that provides researchers the opportunity to easily alter DNA sequences and modify gene function. Its many potential applications include correcting genetic defects, treating and preventing the spread of diseases. Cystic fibrosis (CF) is one of the most common lethal genetic diseases caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Although CF is an old acquaintance, there is still no effective/resolutive cure. Life expectancy has improved thanks to the combination of various treatments, but it is generally below average. Recently, a significant number of additional key medications have become licensed in Europe for the CF treatment including CFTR modulators. But innovative genomically-guided therapies have begun for CF and it is predictable that this will lead to rapid improvements in CF clinical disease and survival in the next decades. In this way, CRISPR-Cas9 approach may represent a valid tool to repair the CFTR mutation and hopeful results were obtained in tissue and animal models of CF disease. |
format | Online Article Text |
id | pubmed-5920621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59206212018-05-04 Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique Marangi, Michele Pistritto, Giuseppa Front Pharmacol Pharmacology One of the most revolutionary technologies in recent years in the field of molecular biology is CRISPR-Cas9. CRISPR technology is a promising tool for gene editing that provides researchers the opportunity to easily alter DNA sequences and modify gene function. Its many potential applications include correcting genetic defects, treating and preventing the spread of diseases. Cystic fibrosis (CF) is one of the most common lethal genetic diseases caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Although CF is an old acquaintance, there is still no effective/resolutive cure. Life expectancy has improved thanks to the combination of various treatments, but it is generally below average. Recently, a significant number of additional key medications have become licensed in Europe for the CF treatment including CFTR modulators. But innovative genomically-guided therapies have begun for CF and it is predictable that this will lead to rapid improvements in CF clinical disease and survival in the next decades. In this way, CRISPR-Cas9 approach may represent a valid tool to repair the CFTR mutation and hopeful results were obtained in tissue and animal models of CF disease. Frontiers Media S.A. 2018-04-20 /pmc/articles/PMC5920621/ /pubmed/29731717 http://dx.doi.org/10.3389/fphar.2018.00396 Text en Copyright © 2018 Marangi and Pistritto. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Marangi, Michele Pistritto, Giuseppa Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique |
title | Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique |
title_full | Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique |
title_fullStr | Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique |
title_full_unstemmed | Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique |
title_short | Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique |
title_sort | innovative therapeutic strategies for cystic fibrosis: moving forward to crispr technique |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920621/ https://www.ncbi.nlm.nih.gov/pubmed/29731717 http://dx.doi.org/10.3389/fphar.2018.00396 |
work_keys_str_mv | AT marangimichele innovativetherapeuticstrategiesforcysticfibrosismovingforwardtocrisprtechnique AT pistrittogiuseppa innovativetherapeuticstrategiesforcysticfibrosismovingforwardtocrisprtechnique |